Live Breaking News & Updates on Innocare Optoelectronics

Stay updated with breaking news from Innocare optoelectronics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib. ....

United States , Hong Kong , New Jersey , Wei Xu , Daobin Zhou , Orelabrutinib Monotherapy , Jianyong Li , Ming Hou , Waldenstrom Macroglobulinemia , Innocare Pharma , Chunhua Lu , American Society Of Hematology , China National Medical Products Administration , Drug Administration , American Society , Annual Meeting , Professor Daobin Zhou , Chronic Lymphocytic , Small Cell Leukemia , Primary Immune Thrombocytopenia , Professor Ming Hou , Refractory Waldenstrom , Refractory Chronic Lymphocytic , Small Lymphocytic Lymphoma , Updated Long Term Results , Selective Bruton ,

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in. ....

Hong Kong , New Jersey , United States , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , National Reimbursement Drug List , China National Medical Products Administration , Drug Administration , China National Healthcare Security Administration , Care Pharma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Mantle Cell Lymphoma , Marginal Zone Lymphoma , Central Nervous System Lymphoma , Breakthrough Therapy Designation , Multiple Sclerosis , Systemic Lupus Erythematosus , Primary Immune Thrombocytopenia ,

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in. ....

Hong Kong , New Jersey , United States , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , National Reimbursement Drug List , China National Medical Products Administration , Drug Administration , China National Healthcare Security Administration , Care Pharma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Mantle Cell Lymphoma , Marginal Zone Lymphoma , Central Nervous System Lymphoma , Breakthrough Therapy Designation , Multiple Sclerosis , Systemic Lupus Erythematosus , Primary Immune Thrombocytopenia ,

InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

/PRNewswire/ InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for its SHP2. ....

Hong Kong , New Jersey , United States , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , Care Pharma , Investigational New Drug , Src Homology , China Based Phase ,

InnoCare Releases 2021 Half Year Results and Business Highlights

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year. ....

United States , Hong Kong , New Jersey , Keymed Biosciences , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , American Society Of Clinical Oncology , Drug Administration , Other Corporate Development , Corporate Development , Shanghai Office , Bund Center , European Society For Medical Oncology , Chinese Society Of Clinical Oncology , Care Pharma , Chinese Society , Clinical Oncology , Treatment Guidelines , Malignant Lymphoma , B Cell Non Hodgkin , European Society , Medical Oncology , Breakthrough Therapy Designation , Orphan Drug Designation , Receptor Tyrosine Kinase ,